Journal
EXPERT REVIEW OF VACCINES
Volume 8, Issue 1, Pages 113-120Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.8.1.113
Keywords
preclinical model; severe combined immunodeficient mice; vaccine development
Categories
Funding
- NIH [CA23766, CA59350]
- Burton Abrams Charitable Trust
- Ryan E McGeough Charitable Fund
- The Aubrey Fund for Pediatric Cancer Research
- The Larry H Smead Foundation
- Commonwealth Foundation for Cancer Research
- The Claire L Tow Chair in Pediatric Oncology Research
- NATIONAL CANCER INSTITUTE [P01CA059350, P01CA023766] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The severe combined immunodeficient (SCID) mouse has no adaptive immunity, lacking mature T and B cells in the peripheral blood or the lymphoid organs. It has been used extensively in biomedical research as a valuable translational model for xeno-engraftment of human tissues and cells. This review focuses on the engraftment of human peripheral blood cells and tissues in SCID mice, as well as in the newly established and more permissive SCID mice deficient in the IL-2 receptor gamma-chain. Human immune responses could be elicited and assessed in these humanized SCID mice upon vaccination or sensitization with allogeneic tissues. A translational model is proposed to attain preclinical data for testing human vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available